A share price of Innate Pharma ADR [IPHA] is currently trading at $2.88, up 21.01%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IPHA shares have gain 19.50% over the last week, with a monthly amount glided 9.09%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 21, March 2024, Innate Pharma Reports Full Year 2023 Financial Results and Business Update. In a post published today on Yahoo Finance, Positive final results of lacutamab TELLOMAK Phase 2 trial in Sézary syndrome presented at ASH Annual Meeting 2023; final data in mycosis fungoides to be shared at an upcoming medical congress.
From an analyst’s perspective:
Innate Pharma ADR [NASDAQ: IPHA] stock has seen the most recent analyst activity on September 03, 2021, when SVB Leerink upgraded its rating to a Outperform but kept the price target unchanged to $7 for it. Previously, SVB Leerink downgraded its rating to Mkt Perform on December 15, 2020, and dropped its price target to $5. On November 24, 2020, Goldman initiated with a Neutral rating and assigned a price target of $4.75 on the stock.
Innate Pharma ADR experienced fluctuations in its stock price throughout the past year between $1.81 and $3.57. Innate Pharma ADR [NASDAQ: IPHA] shares were valued at $2.88 at the most recent close of the market.
Analyzing the IPHA fundamentals
Trailing Twelve Months sales for Innate Pharma ADR [NASDAQ:IPHA] were 56.10M which represents 112.72% growth. Gross Profit Margin for this corporation currently stands at 0.44% with Operating Profit Margin at -0.64%, Pretax Profit Margin comes in at -1.05%, and Net Profit Margin reading is -0.89%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -1.28 and Total Capital is -0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.77.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.54 points at the first support level, and at 2.20 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.06, and for the 2nd resistance point, it is at 3.24.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Innate Pharma ADR [NASDAQ:IPHA] is 3.73. Further, the Quick Ratio stands at 3.84, while the Cash Ratio is 1.78. Considering the valuation of this stock, the price to sales ratio is 4.15, the price to book ratio is 3.67.
